Dunwill Medical is a company with independent intellectual property rights, specializing in the R&D, production and sale of medical diagnostic products, and providing medical testing, individualized treatment protocol and drug research services.
Dunwill medical (Chinese: 顿慧医疗) completed a Series A round of financing worth hundreds of millions of CNY, was jointly led by Lucion (Chinese: 鲁信创投) and Cowin Capital (Chinese: 同创伟业), followed by Qianhai Infrastructure Investment Fund (Chinese: 前海基础), Funway Capital (Chinese: 趣道资产) and Jintou Zhiyuan Private Fund (Chinese: 金投致源).
Founded in 2006, Dunwill Medical’s service covers early cancer diagnosis, drug efficacy monitoring, recurrence early warning and concomitant medication. It integrates product R&D, production, medical inspection and sale.
Dunwill Medical, together with Zhongshan Hospital Affiliated to Fudan University, has developed and transformed 7 kinds of microRNA detection kits (miRNA7TM) to detect liver cancer. It has been listed in the Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2019&2022 Edition) (level 1, higher quality of evidence).
In vitro diagnosis has developed rapidly in the global medical service market for its effectiveness and significant socio-economic benefits. At present, the miRNA liver cancer detection kit from Dunwill has been popularized and applied in third-class hospitals in China.
Dunwill’s competitors include BGI (Chinese:华大基因, 300676), Daan Gene (Chinese: 达安基因, 002030) and Di’an Diagnostics (Chinese: 迪安诊断).